Association between Oral Chinese Herbal Medicine and Recurrence and Metastasis in Patients with Stages II and III Colorectal Cancer: A Cohort Study in China
Table 1
Baseline characteristics of study participants according to quartiles of CHM use.
Q1 (n = 81)
Q2 (n = 12)
Q3 (n = 47)
Q4 (n = 46)
Total (n = 186)
value
Age at diagnosis, years
0.95
18–60
55 (42.3%)
9 (6.9%)
33 (25.4%)
33 (25.4%)
130 (69.9%)
＞60
26 (46.4%)
3 (5.4%)
14 (25%)
13 (23.2%)
56 (30.1%)
Gender
0.62
Female
32 (39.5%)
3 (25.0%)
18 (38.3%)
21 (45.7%)
74 (39.8%)
Male
49 (60.5%)
9 (75.0%)
29 (61.7%)
25 (54.3%)
112 (60.2%)
Tumor site
0.58
Colon
38 (46.9%)
7 (58.3%)
23 (48.9%)
27 (58.7%)
95 (51.1%)
Rectum
43 (53.1%)
5 (41.7%)
24 (51.1%)
19 (41.3%)
91 (48.9%)
Stage and adjuvant chemotherapy
0.003
Stage II without chemotherapy
3 (3.7%)
0 (0)
4 (8.5%)
7 (15.2%)
14 (7.5%)
Stage II with chemotherapy
25 (30.9%)
2 (16.7%)
18 (38.3%)
14 (30.4%)
59 (31.7%)
Stage III without chemotherapy
5 (6.2%)
2 (16.7%)
8 (17.0%)
12 (26.1%)
27 (14.5%)
Stage III with chemotherapy
48 (59.3%)
8 (66.7%)
17 (36.2%)
13 (28.3%)
86 (46.3%)
Syndrome patterns
0.03
Pi (spleen) qi deficiency
42 (51.9%)
8 (66.7%)
21 (44.7%)
25 (54.3%)
96 (51.6%)
Shen (kidney) yin deficiency
12 (14.8%)
0 (0)
4 (8.5%)
4 (8.7%)
20 (10.8%)
Pi (spleen) and Shen (kidney) deficiency
13 (16.0%)
4 (33.3%)
20 (42.6%)
14 (30.4%)
51 (27.4%)
Non-pi (spleen) and Shen (kidney) deficiency
14 (17.3%)
0 (0)
2 (4.3%)
3 (6.5%)
19 (10.2%)
Data are presented as the number (n) and percentage (%). Q: quartiles; CRC: colorectal cancer.
